



# ABC NEWSLETTER

CURRENT EVENTS AND TRENDS IN BLOOD SERVICES

Visit ABC's Web site at: [www.americasblood.org](http://www.americasblood.org)

2023 #36

October 6, 2023

## INSIDE:

WORD IN WASHINGTON .....	2
RESEARCH IN BRIEF.....	3
BRIEFLY NOTED .....	4
PEOPLE.....	4
ABC Advocacy Forum Set for November 1 <sup>st</sup> .....	5
Registration Opens for ADRP's October Webinar.....	5
Register for the ABC WELC Webinar Featuring Dr. Meghan D. Kinter.....	5
Save the Date: SMT Journal Club on December 15 <sup>th</sup> .....	6
MEMBER NEWS.....	6
GLOBAL NEWS .....	7
COMPANY NEWS.....	7
CALENDAR.....	9
EQUIPMENT AVAILABLE .....	10
POSITIONS.....	10

## Does CCP Decrease Chances of Long COVID?

Researchers at Johns Hopkins have [published](#) the findings of a multi-center, randomized trial that evaluated the association “between early COVID-19 convalescent plasma (CCP) treatment, cytokine levels, and post-COVID conditions (PCCs).” According to the [University of Minnesota’s Center for Infectious Disease Research and Policy](#), “[c]ytokines and chemokines are signaling proteins that cells secrete in response to an infection. They trigger immune reactions such as inflammation, which may be excessive or unchecked in COVID-19, potentially leading to long COVID, also called [PCC].”

The published data appears in *mBio*, the peer-reviewed journal of the American Society for Microbiology, as the authors measured “21 different human cytokine and chemokine analytes” in 882 participants at “baseline, day 14, and day 90.”

The study’s primary outcome was, “PCC, which was defined as the presence of any self-reported symptom (cough, fatigue, shortness of breath, headache, neurologic changes, loss of taste, loss of smell, nausea, vomiting, diarrhea, runny/stuffy nose, myalgias, sore throat, chills, fever, or skin manifestations) at the 90-day visit.” The researchers also noted that, “IL-1RA, IL-6, IL-8, IL-15, and MCP-1 were elevated at baseline among those with PCC compared to participants who did not develop PCC.”

The authors explained that, “median age of the 882 subjects was 43 years, with 299 (33.9 percent)  $\geq 50$  years. Five hundred six (57.4 percent) female and 116 Black (13.2 percent) participants were included.” The study found that, “older age, female sex, and baseline elevated IL-6 were associated with PCC... [T]here was a trend for early treatment with CCP to have the lowest odds of PCC (AOR = 0.75 [0.46, 1.23]) compared to early administration of control plasma. [W]hen evaluating only those who received CCP, there was a statistically significant decreased odds of PCC in those who were treated within five days of symptom onset (AOR = 0.60 [0.38, 0.95]) compared to those who received late CCP treatment. There was no statistically significant interaction between CCP treatment and IL-6.”

The researchers stated that, “[t]his study is among the first to show elevation of IL-6 at infection was associated with PCC and that early treatment with CCP for COVID-19 trended toward a lower odds of PCC. Notably, greater levels of IL-6 at baseline were associated with the presence of persistent symptoms at day 90, while early treatment with CCP was associated with lower odds of PCC.”

(continued on page 2)



Does CCP Decrease Long COVID? (continued from page 1)

They acknowledged several limitations of their research including that, “this study was done early in the pandemic when relatively few participants were fully vaccinated. Results may differ among participants who have immunity from prior infection or vaccination.”

**Citation:** Gebo, K., Heath, S., Fukuta, Y. *et al.* “[Early antibody treatment, inflammation, and risk of post-COVID conditions.](#)” *mBio*. 2023.

**WORD IN WASHINGTON**

**The U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) has made [updates](#) to the broad agency announcement (BAA).** The changes aim to modernize and “help facilitate a faster application process for current and potential partners.” Additionally, the updates are “designed to enable BARDA to improve efficiency and responsiveness for advanced research and development proposal submissions and decrease time to award. The new BAA reflects a modernized process to meet the demands of an expanding mission and a growing portfolio of industry partners...The BAA also features revised and [new areas of interest](#) (AOIs), reflecting current open partnership opportunities with BARDA.” AOIs of interest to the blood community include:

- “cellular therapies that could be used to treat acute radiation syndrome and augment the current HHS Health Resources and Services Administration (HRSA) holdings of bone marrow and cord blood to ensure diverse and equitable representation.
- Technologies to produce hematopoietic stem and progenitor cells, including those that optimize directed differentiation and engraftment of functional and safe hematopoietic cells. Activities of interest are those that improve cell processing, optimize ex vivo expansion, and enable scaled up production and GMP manufacturing of human-derived or stem-cell derived blood products.
- Strategies to improve the safety and availability of blood products during a mass casualty incident.
- Therapeutics that can replace blood products to treat hemorrhage or can extend the therapeutic window for resuscitation. Candidates should improve patient outcome, reduce transfusions, be fast acting, and be amenable for use in the field and prehospital space.
- Advanced development, clinical evaluation, and FDA clearance/approval of rapid, accurate, point-of-care, field-useable, CLIA-waivable, molecular diagnostic systems for filoviruses that can, at minimum, detect Ebola virus, Sudan virus, Bundibugyo virus, Marburg virus, and Ravn virus. The ability to differentiate between these viruses is desirable. Assays must detect viral targets at clinically relevant concentrations present during the early stages of disease in whole blood (venous and/or fingerstick), plasma, and/or serum for living patients and after death in oral fluids for cadavers.”

(Source: BARDA [Announcement](#), 9/26/23)

The *ABC Newsletter* (ISSN #1092-0412) is published by America’s Blood Centers® and distributed by e-mail. Contents and views expressed are not official statements of ABC or its Board of Directors. Copyright 2023 by America’s Blood Centers. Reproduction of the *ABC Newsletter* is forbidden unless permission is granted by the publisher (ABC members need not obtain prior permission if proper credit is given).

ABC advocates for and advances policies that promote the role of independent blood centers in providing life-saving blood products and recognizes the continuous need for a safe and robust blood supply. ABC exists to advocate for laws and regulations recognizing the essential role that independent blood centers play in the health care system; promote partnerships, policies, and programs that increase awareness about the need for blood donation; and serve as a thought leader in the advancement of evidence-based medical and scientific solutions related to health and safety.

**America’s Blood Centers**

Chief Executive Officer: Kate Fry  
Chief Medical Officer: Jed Gorlin  
Editor: Mack Benton  
Subscriptions Manager: Leslie Maundy  
**Annual Subscription Rate: \$390**

Send subscription queries to [memberservices@americasblood.org](mailto:memberservices@americasblood.org)  
America’s Blood Centers  
1717 K St. NW, Suite 900, Washington, DC 20006  
Phone: (202) 393-5725  
Send news tips to [newsletter@americasblood.org](mailto:newsletter@americasblood.org).

## RESEARCH IN BRIEF

### Using Donor Populations to Study the Epidemiology & Pathogenesis of Emerging Infectious Diseases.

A review in *Transfusion Medicine Reviews* [covered](#), “five seminal studies that highlight the interplay between transfusion medicine and infectious diseases.” The authors of the review explained that the studies, “were selected for their broad impact within and outside of blood transfusion safety.” The reviewed studies included, “Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis,” published in the *New England Journal of Medicine* in 1989. In this study, “Alter *et al.* showed, conclusively, that transfusion transmitted non-A/non-B hepatitis was primarily due to hepatitis C (HCV).” The next study featured was, “Dynamics of HIV viremia and antibody seroconversion in plasma donors implications for diagnosis and staging of primary HIV infection,” published in *AIDS* in 2003. In this study, “Fiebig *et al.*, analyzed 51 human immunodeficiency virus (HIV) antibody seroconversion (SC) panels comprised of 435 samples...The study defined successive stages of acute HIV infection...The Fiebig staging system advanced the understanding of early HIV infection dynamics from diagnostic (including blood screening), pathogenesis, vaccine and therapeutic trial perspectives.” The third study, “Virus and antibody dynamics in acute West Nile Virus infection,” was published in *The Journal of Infectious Diseases* in 2008. “To determine the dynamics of the early stages of West Nile Virus (WNV) infection, Busch *et al.*, followed newly infected blood donors identified by nucleic acid amplification testing (NAT) using a highly sensitive transcription-mediated amplification (TMA) assay.” The authors “demonstrated that a substantial number of donations with low-level viremia after seroconversion were being transfused despite implementation of MP-NAT...The study’s findings have broad implications for clinical diagnosis, pathogenesis, transfusion safety, and epidemiology of WNV infection.” The next study, “Screening for Babesia microti in the U.S. Blood Supply,” was published in the *New England Journal of Medicine* in 2016. “Testing for B. microti antibodies and DNA was conducted on a proportion of donors allowing comparison of recipients of tested vs. untested components...Donor testing significantly decreased the risk of hospital reported transfusion transmission (0/75,331 in tested vs 14/253,031 in untested blood;  $p = 0.05$ )...The test system, using parasite DNA by PCR, was subsequently licensed by the FDA.” The final study included in the review, “Estimated U.S. infection- and vaccine-induced SARS-CoV-2 seroprevalence based on blood donations, July 2020-May 2021,” was published in *JAMA* in 2021. “At the outset of the SARS-CoV-2 pandemic, a large-scale collaboration was established between the U.S. Centers for Disease Control and Prevention and multiple blood collection organizations in the U.S., the National Blood Donor Seroprevalence (NBDS) Study.” The authors of this study, “demonstrated value of the public-private collaboration of CDC and multiple blood donor collection organizations, enabling access to large numbers of high-quality samples from asymptomatic individuals (i.e., blood donors) unselected for risk of exposure to a new infectious agent (in this case, SARS-CoV-2)...This shows the feasibility of rapidly establishing networks to facilitate sample capture, testing and analysis.” The review concluded that, “beyond blood safety, blood donor populations offer enormous value to characterize [both] established and emerging infectious diseases.”

**Citation:** Bloch E.M., Busch, M.P., Corash, L.M. *et al.* “[Leveraging donor populations to study the epidemiology & pathogenesis of transfusion transmitted and emerging infectious diseases.](#)” *Transfusion Medicine Reviews*. 2023.

Contributed by Richard Gammon, MD, Medical Director at OneBlood 💧

### ABC Calendar of Events

ABC offers a variety of meetings, workshops and virtual opportunities for education and networking as well as participation in ABC business. The [calendar of events](#) includes annual and summer meetings, board meetings, workshops, and webinars, and details will be updated as confirmed. We look forward to your support and participation!



## BRIEFLY NOTED

**Preprint (non-peer reviewed) research [studying](#) the “viral replication and disease progression in SARS-CoV-2 infected hamsters treated with COVID-19 convalescent plasma (CCP) obtained from recovered patients subsequently vaccinated with an mRNA vaccine (Vaxplas)” is available.** The authors of the research explained that, “infusion of hamsters 24 hours after SARS-CoV-2 infection with moderate titer CCP and high titer Vaxplas blunts virus replication in the lungs and improves the course of viral disease.” Additionally, they noted that, “we found that although normal plasma has no effect on clinical disease (weight loss) or virus replication in hamsters, it does decrease the severity and extent of inflammation in the lungs.”

**Citation:** Carroll, T., Wong, T., Morris, M.K., *et al.* “[Administration of vaccine-boosted COVID-19 convalescent plasma to SARS-CoV-2 infected hamsters decreases virus replication in lungs and hastens resolution of the infection despite transiently enhancing disease and lung pathology.](#)” 2023. 💧

## PEOPLE

**[Martin Cannon](#)**, founder of Hemanext, Inc., has retired as chief executive officer (CEO). According to a company news release, Mr. Cannon is, “the visionary leader who founded Hemanext in 2008 with support from a National Institutes of Health (NIH) grant, leaves an enduring legacy. His exceptional foresight in recognizing the potential for enhancing red blood cell (RBC) quality, at a time when our understanding of quality drivers and clinical correlations was limited, drove the development of the company from an idea and a team of two to its recognition as the leading innovator in blood quality. Mr. Cannon’s unwavering commitment to improving RBC quality, combined with his profound understanding of its vital role in improving the care of millions of patients worldwide, has led to the transformation of the hypoxic storage of RBCs from a concept into a commercially viable medical device.”

(Source: Hemanext [News Release](#), 9/18/23)

**[Andrew Dunham, PhD](#)**, has been named CEO of Hemanext. Dr. Dunham most recently served as the company’s chief technology officer. According to a company news release, Dr. Dunham has “been an integral part of the company’s success story, assumes the role of CEO. [He] joined Hemanext in 2015 as vice president of Clinical & Scientific Affairs and, over the past eight years, has played a key role in developing a scientific platform to characterize the biological and biochemical differences between hypoxic and conventional RBCs.”

(Source: Hemanext [News Release](#), 9/18/23) 💧

### NEW on CollABOrate

# COLLABORATE

SHARE STRATEGIC ADVICE | SOLVE CHALLENGES | DEVELOP NEW APPROACHES

Recent discussion topics on the ABC [CollABOrate](#) Online Member Community include:

- [Procedure Change Process](#) (COLLECTIONS & DONOR SERVICES)
- [Platelet Agitator/Incubators](#) (TECHNICAL DIRECTORS)
- [Proficiency Testing for Sysmex XN with Blood Bank Module](#) (TECHNICAL DIRECTORS)
- [Donor Collections Training-completed Phlebotomies for Training](#) (MEMBER EMPLOYMENT TRAINING AND DEVELOPMENT)

ABC members are encouraged to [login](#) and join the conversations today!



**America's Blood Centers®**  
It's About *Life.*

## INSIDE ABC

*The programs and services described in the Inside ABC section are available to ABC member blood centers and their staffs only, unless otherwise specified.*

### **ABC Advocacy Forum Set for November 1<sup>st</sup>**

America's Blood Centers (ABC) will hold its next Advocacy Forum: Congressional, Agency, and State Updates on Nov. 1<sup>st</sup> from 2-3 p.m. EDT. The forum will include updates and discussions on:

- the ABC meeting on surge capacity and preparedness with the Biomedical Advanced Research and Development Authority (BARDA) and the Office of the Assistant Secretary for Preparedness and Response (ASPR);
- congressional updates;
- licensure reform efforts; and
- state advocacy and the ABC Council of States.

Additional information including a link to registration is available to ABC members in [MCN 23-083](#).

(Source: [MCN 23-083](#), 10/5/23)

### **Registration Opens for ADRP's October Webinar**

Join ADRP, the Association for Blood Donor Recruitment Professionals on Wednesday, October 25th at 1 p.m. EDT for the "[Innovations in Donor Recruitment and Inventory Growth](#)" webinar. This event will feature successful case studies from blood center professionals as they describe the creative programs and incentives that their blood centers have implemented, while taking risks that ultimately resulted in substantial inventory boosts. This strategy ensured that their local hospital partners consistently had blood products on their shelves, especially during challenging times of the year. [Registration](#) is open. Donor recruitment professionals will find this webinar particularly enriching, as speakers share data, results, and new and effective ways that can help you meet your collection goals. Join us to hear speakers from:

- Our Blood Institute;
- LifeSouth Community Blood Centers;
- ConnectLife; and
- Memorial Blood Centers.

### **Register for the ABC WELC Webinar Featuring Dr. Meghan D. Kinter**

America's Blood Centers (ABC) [Women's Executive Leadership Community](#) (WELC) will host its first [webinar](#), titled "Taming the Tyranny of the Urgent," on October 26<sup>th</sup> at 2 p.m. EDT. Meghan D. Kinter, PhD, will be the guest speaker. This webinar will feature breakout sessions for attendees and a question-and-answer session with Dr. Kinter who has, according to her bio, spent more than two decades "expertly guid[ing] businesses and individuals through the complexities of their challenges, helping them navigate from feeling 'stuck' to achieving clarity and momentum." By the end of the event, attendees will discover the Power of the 3Ms – Mindful Mindset, Managing Time, and Mastering Habits, understand the psychology behind urgency and its impact on productivity, develop a resilient, proactive approach to daily challenges, and curate a personal toolkit of habits, tools, and strategies to optimize every day. WELC

(continued on page 6)



## INSIDE ABC (continued from page 5)

is a complimentary offering open to all employees of ABC member blood centers and ABC sponsor partners. Through this initiative, ABC strives to empower leaders throughout the blood community through networking and professional development. ABC encourages eligible individuals to [join](#) WELC and its [LinkedIn Community](#), and share this information with those who may be interested.

### Save the Date: SMT Journal Club on December 15<sup>th</sup>

The next ABC Scientific, Medical, and Technical Journal Club Webinar will take place on December 15<sup>th</sup> from 12-1:15 p.m. EST. The webinar is free to all ABC members. An email announcement with a registration link and the articles to be reviewed on the webinar is forthcoming. 💧

## MEMBER NEWS

**New York Blood Center Enterprises** (NYBCe) has [acquired](#) Talaris Therapeutics, Inc. According to a news release the transaction includes, “[the] acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe’s Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental U.S. capable of serving the biopharma industry and large hospital systems.” NYBCe President and Chief Executive Officer (CEO) Christopher Hillyer, MD added in the news release, “I am exceptionally pleased with this strategic expansion of our CCS portfolio, which now allows NYBCe to have in-house start-to-finish cell and gene therapy, and regenerative medicine, development and manufacturing capabilities. Our new facilities and expert teams are located within key geographies, with best-in-class GMP manufacturing, and a close-to-patient transportation network as well as leading academic medical centers, which will allow us to fast-track lifesaving therapies to hospital systems.” The news released stated that the, “Louisville, Kentucky facility adds approximately 20,000 sq. ft. with quality control and Phase 3-fitted GMP manufacturing capacity. The space provides ISO 7 cleanrooms, vast GMP capacity, cryopreservation, and storage and warehouse space, a robust digital chain of identity systems, supported by rigorous testing and release procedures. The Houston, Texas facility offers another 6,000 sq. ft. of analytical and process development capacity enhancing NYBCe’s expertise in broad analytical methodologies across cell types, viral vectors, mRNA, and gene expression analysis.”

(Source: NYBCe [News Release](#), 10/4/23)

The **Alliance for Community Transfusion Services (ACTS)** has officially joined America’s Blood Centers (ABC). The organization has been approved for Organizational Affiliate Membership, which is granted to an organization other than a blood center that supports the mission of ABC in serving the common good of donors who wish to make an altruistic gift and the blood recipients who benefit from their donations. More information about ABC membership can be found [here](#).

**Héma-Québec** [celebrated](#) its 25<sup>th</sup> anniversary on September 28<sup>th</sup>. In recognition of this milestone, the blood center has, “launched a [microsite](#) that hosts a podcast, *Donneurs de sens*, including nine episodes filled with information about various aspects of the organization’s mission. The anniversary will also be in the spotlight during various events organized this year for donors, volunteers, employees, and partners.” Héma-Québec President and CEO added in the news release, “without all the members of the great Héma-Québec family, nothing of all that has been accomplished in the past 25 years would have been possible. Together, we must take advantage of these milestones to take a step back and encourage each other to continue to give our

(continued on page 7)



## MEMBER NEWS (continued from page 6)

best. It is also an opportunity to look to the future because we aren't short on projects and especially ambition to continue developing and always doing better, in serving Québec's population." The organization was formed by the Québec government and became "the exclusive supplier for blood products and medications manufactured from plasma for people in the province."

(Source: Héma-Québec [News Release](#), 9/28/23)

**MEDIC Regional Blood Center** recently [announced](#) that board member and blood donor [James Harrison](#) is participating in an initiative to raise awareness for sickle cell disease and blood donation. Mr. Harrison is training for and running the Covenant Health Knoxville Marathon on April 7<sup>th</sup>, 2024. By that date, he has a goal to not only complete the marathon, but also inspire 10,000 blood donations from individuals worldwide. All eligible individuals are encouraged to participate in this initiative by making a blood donation and tracking it using the hashtag #1dadcan or via the sign-up form on the MEDIC Regional Blood Center [website](#). Two of Mr. Harrison's three children are living with sickle cell disease. "He has been working closely with MEDIC staff since early 2022 on education and outreach to the Knoxville community about the importance of blood donations for Sickle Cell patients of all ages."

(Source: MEDIC Regional Blood Center News Release, 9/21/23) ◆

## GLOBAL NEWS

**The World Health Organization (WHO)** [published](#) a recommendation for a new vaccine to prevent malaria in children. According to a news release, the R21/Matrix-M "is the second malaria vaccine recommended by WHO, following the RTS,S/AS01 vaccine, which received a WHO recommendation in 2021. Both vaccines are shown to be safe and effective in preventing malaria in children and, when implemented broadly, are expected to have high public health impact." The recommendation "follows advice from the WHO: Strategic Advisory Group of Experts on Immunization (SAGE) and the Malaria Policy Advisory Group (MPAG) and was endorsed by the WHO Director-General."

(Source: WHO [News Release](#), 10/2/23)

**The United Nations Office for Project Services (UNOPS)** has [collaborated](#) with Novo Nordisk to provide Mykolaiv Regional Blood Transfusion Station in Ukraine with equipment including "automated blood separator, a whole blood processing platform, and other essential equipment used to automate various stages of blood extraction and processing, which will significantly increase output and improve the quality of services." The collaboration is part of a \$1.3 million initiative, "[that] will enable the station to serve up to 40,000 patients with life-threatening conditions annually." Valerii Chyniakov, director of the Mykolayiv Regional Blood Transfusion Station, added in the news release, "we have been under increased pressure to meet the demand for blood components. Medical professionals rely on us to provide them with what's needed to save lives. The new equipment will go a long way in helping us with the current situation, and it's also a significant long-term contribution to the region's healthcare system."

(Source: UNOPS [News Release](#), 9/18/23) ◆

## COMPANY NEWS

**Fresenius Kabi** received a warning [letter](#) from the U.S. Food and Drug Administration (FDA) regarding "significant deviations from current good manufacturing practice (CGMP) requirements in the manufacture of your blood-pack units (BPUs) with and without in-line leukoreduction filters, as well as Alyx component

(continued on page 8)

COMPANY NEWS (continued from page 7)

solutions, Amicus component solutions, and InterSol, a platelet additive solution.” A Fresenius Kabi spokesperson told *Becker’s Healthcare* in a [statement](#), “[w]e take the [findings] very seriously, and we share the [goal] to protect public health. As one of the leading developers and manufacturers of products for transfusion medicine and cell therapy, we are committed to working with public health experts, blood collectors, regulators, and others to ensure the safest possible experience for donors and recipients.”

(Sources: FDA [Warning Letter](#), 9/14/23; *Becker’s Healthcare*, “[CDC ties fatal sepsis cases to Fresenius Kabi plant](#),” 10/5/23)

**Takeda** [announced](#) this week that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization has recommended the company’s live, attenuated dengue vaccine for children 6 to 16 years of age in areas of high dengue burden and transmission. According to a news release from Takeda, the SAGE additionally recommended that:

- “[with the aforementioned age range] the vaccine should be introduced about 1-2 years prior to the age-specific peak incidence of dengue-related hospitalizations. The vaccine should be administered in a two-dose schedule with a three-month interval between doses; and
- the vaccine introduction should be accompanied by a well-designed communication strategy and community engagement.”

The SAGE recommendations were based on data from several clinical trials including the phase III Tetra-valent Immunization against Dengue Efficacy Study (TIDES) trial in which “[the study’s] primary endpoint of overall vaccine efficacy (VE) against virologically-confirmed dengue (VCD) with 80.2 percent efficacy at 12-months follow-up. The trial also met all secondary endpoints for which there were a sufficient number of dengue cases at 18-months follow-up. The VE result in preventing hospitalization due to VCD fever was 90.4 percent. Through four and a half years (54 months after the second dose) in an exploratory analysis, [the vaccine] demonstrated continued overall protection, with sustained overall VE of 61.2 percent and 84.1percent VE against VCD and hospitalized dengue, respectively. Observations of VE varies by serotype and remained consistent with previously reported results. [The vaccine] has been generally well tolerated and no important safety risks have been identified in the TIDES trial, to date.

(Source: Takeda [News Release](#), 10/3/23) 💧

### Upcoming ABC Webinars & Virtual Events – Don’t Miss Out!

- **ADRP Webinar: Innovations in Donor Recruitment and Inventory Growth** – Oct. 25. [Registration](#) is open. More information available [here](#).
- **ABC Women’s Executive Leadership Community (WELC) Webinar** – Oct. 26. More information and a link to registration are available to ABC Members in [MCN 23-081](#).
- **ABC Advocacy Forum: Congressional, Agency, and State Updates** – Nov. 1. More information and a link to registration are available to ABC Members in [MCN 23-083](#).
- **ABC Scientific, Medical, and Technical Journal Club Webinar** – Dec. 15. More information coming soon!
- **2023 ADRP International Showcase** – Nov 15. [Registration](#) is open. More information available [here](#).





## CALENDAR

*Note to subscribers: Submissions for a free listing in this calendar (published weekly) are welcome. Send information to [newsletter@americasblood.org](mailto:newsletter@americasblood.org). (For a more detailed announcement in the weekly "Meetings" section of the newsletter, please include program information.)*

### 2023

Oct. 9-11. **Advanced Medical Technology Association (AdvaMed) The MedTech Conference, Anaheim, Calif.** [Registration](#) is open. More information available [here](#).

Oct. 10-11. **Biomedical Excellence for Safer Transfusion (BEST) Meeting LXVI, Nashville, Tenn.** More information available [here](#).

Oct. 11-14. **Sickle Cell Disease Association of America 51<sup>st</sup> Annual National Convention, Arlington, Va.** [Registration](#) is open. More information available [here](#).

Oct. 14-17. **AABB Annual Meeting, Nashville, Tenn.** [Registration](#) is open. More information available [here](#).

Oct. 18-20. **American Society for Clinical Pathology (ASCP), Long Beach, Calif.** More information available [here](#).

Oct. 25. **ADRP, The Association for Blood Donor Professionals Webinar: Innovations in Donor Recruitment and Inventory Growth.** [Registration](#) is open. More information available [here](#).

Oct. 26. **America's Blood Centers (ABC) Women's Executive Leadership Community (WELC) Webinar.** More information and a link to registration are available [here](#).

Oct. 31. **U.S. Food and Drug Administration (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee Meeting (Virtual).** More information available [here](#).

Nov 1. **ABC Advocacy Forum: Congressional, Agency, and State Updates (Virtual).** More information and a link to registration are available [here](#).

Nov. 13-14. **U.S. Department of Health and Human Services (HHS) Biomedical Advanced Research and Development Authority (BARDA) Industry Day 2023. (Hybrid), Washington, D.C.** [Registration](#) is open. More information available [here](#).

Nov 15. **ADRP, The Association for Blood Donor Professionals International Showcase (Virtual).** [Registration](#) is open. More information available [here](#).

Nov. 18-21. **ISBT Regional Congress, Cape Town, South Africa.** [Registration](#) is open. More information available [here](#).

Dec. 15. **ABC Scientific, Medical, Technical (SMT) Journal Club Webinar.** More information coming soon.

### 2024

Feb.7-8. **International Plasma and Fractionation Association & EBA Symposium on Plasma Collection and Supply, Leiden, Netherlands.** [Registration](#) is open. More information available [here](#).

Mar. 4-6. **ABC Annual Meeting, Arlington, Va.** More information available [here](#).

April 12-13. **BEST Meeting, Amsterdam, Netherlands.** More information coming soon.

May 14-16. **2024 ADRP Annual Conference, St. Louis, Mo.** More information available [here](#). 💧

## CLASSIFIED ADVERTISING

Classified advertisements, including notices of positions available and wanted, are published free of charge for a maximum of three weeks per position per calendar year for ABC members. There are charges for non-members: \$139 per placement for ABC Newsletter subscribers and \$279 for non-subscribers. A six (6) percent processing fee will be applied to all credit card payments. Notices ordinarily are limited to 150 words. To place an ad, e-mail: [newsletter@americasblood.org](mailto:newsletter@americasblood.org)

## EQUIPMENT AVAILABLE

**For Sale.** Two refurbished Aurora Plasmapheresis System devices with Certificate of Compliance for each device. Both devices have Software 2.0 installed. Asking for best offer. Location: Jackson, TN. Please contact LaTrina Morman, (731) 427-4431, or email [latrinamorman@lifelinebloodserv.org](mailto:latrinamorman@lifelinebloodserv.org).

**For Sale.** Two NEW Aurora Plasmapheresis System devices with Certificate of Compliance. NEVER USED. Currently, both have Software 2.0 installed. Asking for best offer. Location: Jackson, TN. Please contact LaTrina Morman, (731) 427-4431, or email [latrinamorman@lifelinebloodserv.org](mailto:latrinamorman@lifelinebloodserv.org).

## POSITIONS

### **Phlebotomist 2 – Donor Centers (Carter BloodCare).**

**Principal Accountability:** The Phlebotomist 2 assists in smooth and efficient donor flow, determine donor acceptability, performs sterile venipuncture for the collection of blood, provides excellent customer service and ensures compliance with regulations and standard operating procedures throughout the donation process. In the absence of a supervisor, this position will oversee and assign responsibilities to collections staff, except for hiring and/or terminations. This includes effectively and discreetly solving personnel and donor problems, addressing procedural or behavioral problems, and making verbal or written reports to management. Additionally, the Phlebotomist 2 will be required to attend and complete annual leadership/development training resources, to mentor/assist with on-the-job development of new employees and subordinate staff. This position may be required to participate in special projects or programs. Regular full-time attendance is required during operational hours. Education: High school diploma or equivalent. Some college a plus. Experience: One-year general work experience, preferably working with the public, or education that includes comparable experience such as an internship or externship. Customer service experience required, intern and/or externship experience will satisfy this requirement. Previous Phlebotomy 1, blood banking experience or medical field experience. Background in a highly regulated industry. Bilingual skills and CDL driver a plus. Equal Opportunity Employer: Disability/Veteran. Apply at [www.carterbloodcare.org](http://www.carterbloodcare.org), click Careers & search for job # Phlebotomist 2.

**Purchasing Manager.** LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference. The Purchasing Manager at our headquarters location in Gainesville, FL is responsible for vendor selection, negotiation, establishment and maintenance of all purchased materials, supplies, equipment, and services used by the company. The Purchasing Manager oversees daily operations of the Purchasing team, is organized and

decisive, and can motivate the team to reach daily and long-range goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

**Employee Relations Manager.** LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management and HR experience, and a passion for making a difference. The Employee Relations Manager at our headquarters location in Gainesville, FL is responsible for facilitating employee relations and resolving personnel issues. The Employee Relations Manager deals with grievances and violations invoking disciplinary action, provides guidance, advice, and support to managers and employees on HR related issues, and oversees the work of eight Human Resources Coordinators. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

**Immunohematology Reference Lab Manager.** LifeSouth Community Blood Centers is seeking an individual who enjoys leading a team of lab professionals dedicated to providing high quality products and services for patients. Our Birmingham, AL IRL is supported by Board Certified Pathologists in Transfusion Medicine, and by LifeSouth's accredited HLA Lab, Molecular Lab, and IRLs in Gainesville, FL and Atlanta, GA. The IRL Manager is responsible for providing onsite day-to-day supervision of testing personnel, ensuring compliance with regulatory agency requirements, and reporting of test results under the direction of the laboratory director. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

(continued on page 11)

POSITIONS (continued from page 10)

**Regional Manager.** LifeSouth Community Blood Centers is seeking a highly skilled leader with proven management experience and a passion for making a difference in the community. The Regional Manager in The Villages, FL, oversees daily operations of the region, is organized and decisive, and can motivate the team to reach daily and long-range blood collection goals. Join our team and help us continue our dedication to making sure the blood is there when you or your family is in need. Visit our careers page to learn more about this position, and [apply here!](#)

**Medical Director (Memorial Blood Centers).** Memorial Blood Centers (MBC.ORG), a division of Innovative Blood Resources, now a major partner in the NYBC Enterprise, has been saving and sustaining lives since 1948, and we're seeking a Medical Director who will help further our efforts and expand our success. This challenging medical directorship serves as co-medical director at a nationally recognized Children's hospital transfusion service, a national quality leading safety net hospital that is the largest local level 1 trauma center (both adult and pediatric), and associate medical director for blood centers in Minnesota (Duluth and Twin Cities, Nebraska (Lincoln and Omaha) and Greater Kansas City (Kansas and Missouri). The role will provide medical support across the Enterprise and for the assigned blood centers and transfusion services. Memorial Blood Centers supplies blood and blood components, state-of-the-art laboratory services, and biomedical expertise to area healthcare partners, national blood centers, biotechnology companies, research institutions, and international clients. The blood centers in Minnesota, Nebraska and the Greater Kansas City area serve nearly 100 hospitals and more than a dozen air ambulances with life-saving blood. Ample opportunity for research and clinical publication as well as direct patient and donor involvement. Click here to apply: <https://www.kleinherhsh.com/positions/medical-director-2/>. 💧